These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9443356)

  • 41. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The other side of the histamine H3 receptor.
    Ellenbroek BA; Ghiabi B
    Trends Neurosci; 2014 Apr; 37(4):191-9. PubMed ID: 24636456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service.
    Kamin J; Manwani S; Hughes D
    Psychiatr Serv; 2000 Mar; 51(3):287-9. PubMed ID: 10686232
    [No Abstract]   [Full Text] [Related]  

  • 44. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease.
    Cazorla M; Kang UJ; Kellendonk C
    Mov Disord; 2015 Jun; 30(7):895-903. PubMed ID: 26018615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episode.
    Bonoldi I; Howes OD
    Adv Pharmacol; 2013; 68():199-220. PubMed ID: 24054146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia.
    Pedro BM; Pilowsky LS; Costa DC; Hemsley DR; Ell PJ; Verhoeff NP; Kerwin RW; Gray NS
    Psychol Med; 1994 May; 24(2):423-9. PubMed ID: 8084937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognition and Dopamine D
    Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC; Graff-Guerrero A
    Am J Geriatr Psychiatry; 2017 Jan; 25(1):1-10. PubMed ID: 27745822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
    Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
    J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Hit-and-Run" actions at dopamine receptors, part 2: Illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Oct; 62(10):747-8. PubMed ID: 11816862
    [No Abstract]   [Full Text] [Related]  

  • 50. Implications of basal ganglionic dysfunction for schizophrenia.
    Lidsky TI; Weinhold PM; Levine FM
    Biol Psychiatry; 1979 Feb; 14(1):3-12. PubMed ID: 420906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The course of neuropsychological impairment and brain structure abnormalities in psychotic disorders.
    Woodward ND
    Neurosci Res; 2016 Jan; 102():39-46. PubMed ID: 25152315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study.
    Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Murray RM; Kerwin RW
    Br J Psychiatry; 1994 Jan; 164(1):16-26. PubMed ID: 8137105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurotransmitters and CNS disease. Schizophrenia.
    Snyder SH
    Lancet; 1982 Oct; 2(8305):970-4. PubMed ID: 6127468
    [No Abstract]   [Full Text] [Related]  

  • 56. The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia.
    Takase M; Kanahara N; Oda Y; Niitsu T; Watanabe H; Iyo M
    Schizophr Res; 2017 Dec; 190():182-183. PubMed ID: 28285026
    [No Abstract]   [Full Text] [Related]  

  • 57. Are dopamine D2 receptors out of control in psychosis?
    Seeman P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():146-52. PubMed ID: 23880595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trauma and the psychosis spectrum: A review of symptom specificity and explanatory mechanisms.
    Gibson LE; Alloy LB; Ellman LM
    Clin Psychol Rev; 2016 Nov; 49():92-105. PubMed ID: 27632064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal microstructures of the basal ganglia in schizophrenia revealed by diffusion tensor imaging.
    Hashimoto R; Mori T; Nemoto K; Moriguchi Y; Noguchi H; Nakabayashi T; Hori H; Harada S; Kunugi H; Saitoh O; Ohnishi T
    World J Biol Psychiatry; 2009; 10(1):65-9. PubMed ID: 19253093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathology, phenomenology and the dopamine hypothesis of schizophrenia.
    McKenna PJ
    Br J Psychiatry; 1987 Sep; 151():288-301. PubMed ID: 3322465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.